Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Merck and : Biothera Pharmaceuticals Announces Presentations on Imprime PGG at Three Upcoming Healthcare Conferences

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/03/2017 | 01:45pm CET

Release date- 02102017 - EAGAN, MN - Biothera Pharmaceuticals, Inc. today announced that it will present new research at three upcoming healthcare conferences for Imprime PGG, Biothera's novel phase 2 cancer immunotherapy.

These presentations will provide data strengthening the scientific foundation for the use of Imprime PGG in combination with immune checkpoint inhibitors. The high profile late-breaking session of the AACR-NCI- EORTC will feature initial translational research from Biothera's ongoing phase 2 clinical study combining Imprime PGG and Merck's anti-PD-1 antibody, Keytruda, for the treatment of biomarker-positive patients with triple negative breast cancer or metastatic melanoma.

About Biothera Pharmaceuticals Inc.

Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a Phase 2 cancer immunotherapy that enhances the efficacy of anti-cancer immune response in combination with immune checkpoint inhibitor, tumor-targeting and anti-angiogenesis antibodies. Biothera Pharmaceuticals has clinical research agreements with Merck to evaluate Imprime PGG and KEYTRUDA in Phase 2 studies in advanced melanoma, metastatic triple negative breast cancer, and head and neck squamous cell cancer. This therapeutic combination also is the focus of a Big Ten Cancer Research Consortium Phase 1b/2 trial in patients with non-small cell lung cancer. Imprime PGG has demonstrated a favorable safety profile in more than 400 subjects and signals of activity in multiple combinations and tumor types.

Contact:

David Walsh

Tel: 651-256-4606

Email: [email protected]

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
03:29p MERCK AND : FDA Accepts Supplemental Biologics License Application (sBLA), Assig..
02:11p MERCK AND : Neon Therapeutics Announces Clinical Trial Collaboration with Merck
01:27p Merck raises stakes in lung cancer as rivals close in
12:38p MERCK AND : FDA Accepts Supplemental Biologics License Application (sBLA), Assig..
07:32a ROCHE : Tecentriq cocktail slows kidney cancer progression
12/09 EISAI : Updated Analysis of Phase Ib/II Study of Eribulin and Pembrolizumab Comb..
12/08 MERCK AND : New England Journal of Medicine Publishes Phase 3 Clinical Study of ..
12/07 Sage Therapeutics, Dollar General jump; LendingClub tumbles
12/07 Roche drug cocktail doubles chance of holding lung cancer at bay
12/07 DOW MOVERS : Jpm, mrk
More news
News from SeekingAlpha
12/10 BIOTECH IN 2018 : Will Repatriated Cash Fuel A Feeding Frenzy?
12/08 Halaven/Keytruda combo shows 26% response rate in TNBC study
12/08 73 Dividend Growth Stocks Going Ex-Dividend Next Week
12/06 Merck weak ahead of Roche data release from late-stage study of Tecentriq in ..
12/06 3 THINGS IN BIOTECH YOU SHOULD LEARN : December 6, 2017
Financials ($)
Sales 2017 40 235 M
EBIT 2017 13 721 M
Net income 2017 5 246 M
Debt 2017 13 787 M
Yield 2017 3,40%
P/E ratio 2017 27,22
P/E ratio 2018 17,87
EV / Sales 2017 4,11x
EV / Sales 2018 3,99x
Capitalization 152 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 65,4 $
Spread / Average Target 18%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Roy D. Baynes Chief Medical Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY-7.68%151 559
JOHNSON & JOHNSON21.23%377 698
NOVARTIS11.34%218 728
PFIZER9.48%213 036
ROCHE HOLDING LTD.6.19%208 877
AMGEN18.98%127 332